Search Within

Rui Wang

Formats
  1. Journal Article (12)
  2. Meeting Abstract (10)
  3. Book Section (1)
  4. Miscellaneous (1)
Groups
  1. Breast Medicine Service (24)
  2. Department of Medicine (24)
  3. Solid Tumor Oncology Division (24)
  4. Survivorship Research (16)
  5. Epidemiology and Biostatistics (14)
  6. Biostatistics Service (11)

More Groups

People
  1. Chau Dang (8)
  2. Sujata Patil (8)
  3. Clifford Hudis (6)
  4. Shanu Modi (6)
  5. Larry Norton (5)
  6. Komal Jhaveri (4)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (5)
  6. 2018 (5)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Annals of Surgical Oncology (3)
  3. Cancer Research (2)
  4. The Oncologist (2)
  5. American Journal of Hematology/Oncology (1)
  6. Breast Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. Springer (4)
  3. American Association for Cancer Research (3)
  4. Elsevier Inc. (2)
  5. Oxford University Press (2)
  6. Biomed Central Ltd (1)

More Publishers

Results (24)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow-up
    Journal Article

    Wang, R.; Smyth, L. M.; Iyengar, N.; Chandarlapaty, S.; Modi, S.; Jochelson, M.; Patil, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases
    Meeting Abstract

    Bacotti, A.; Wang, R.; Deal, A. M.; Prince, G.; McKee, M. J.; Moschos, S. J.; Brogi, E.; Morikawa, A.; Anders, C. K.; Seidman, A. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2-targeted therapy: An argument for earlier detection
    Journal Article

    Morikawa, A.; Wang, R.; Patil, S.; Diab, A.; Yang, J.; Hudis, C. A.; McArthur, H. L.; Beal, K.; Seidman, A. D.
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of poorly differentiated (PD) grade 3 (G3) gallbladder neuroendocrine carcinomas (NEC): A single institution experience
    Meeting Abstract

    Corbett, V.; Wang, R.; Lowery, M.; Reidy-Lagunes, D.; Raj, N.
    Pancreas (2018)

    Fulltext@MSK | Save
  • The choose of different surgical therapies of hepatic alveolar echinococcosis: A single-center retrospective case-control study
    Journal Article

    Chen, K. F.; Tang, Y. Y.; Wang, R.; Fang, D.; Chen, J. H.; Zeng, Y.; Li, B.; Wen, T. F.; Wang, W. T.; Wu, H.; more...
    Medicine (2018)

    Fulltext@MSK | Save
  • Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer
    Meeting Abstract

    Wang, R.; Yu, A. F.; Steingart, R.; Patil, S.; Baselga, J.; Norton, L.; Hudis, C.; Dang, C. T.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Wang, R.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; more...
    Breast Cancer Research (2017)

    Fulltext@MSK | Save
  • Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer
    Journal Article

    Yu, A. F.; Singh, J. C.; Wang, R.; Liu, J. E.; Eaton, A.; Oeffinger, K. C.; Steingart, R. M.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2017)

    Fulltext@MSK | Save